USD
$0.00
(0.00%
)At Close (As of Sep 17, 2025)
$3.24B
Market Cap
-
P/E Ratio
-4.04
EPS
$169.49
52 Week High
$93.58
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $156M |
Total Revenue | $167M |
Cost Of Revenue | $11M |
Costof Goods And Services Sold | $11M |
Operating Income | -$23M |
Selling General And Administrative | $79M |
Research And Development | $21M |
Operating Expenses | $179M |
Investment Income Net | - |
Net Interest Income | $5M |
Interest Income | $8.1M |
Interest Expense | $3M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $35M |
Income Before Tax | $2.5M |
Income Tax Expense | $6.6M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$4M |
Comprehensive Income Net Of Tax | - |
Ebit | $5.6M |
Ebitda | $41M |
Net Income | -$4M |
Field | Value (USD) |
---|---|
Total Assets | $942M |
Total Current Assets | $332M |
Cash And Cash Equivalents At Carrying Value | $72M |
Cash And Short Term Investments | $72M |
Inventory | $14M |
Current Net Receivables | $42M |
Total Non Current Assets | $610M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $267M |
Intangible Assets Excluding Goodwill | $267M |
Goodwill | $105M |
Investments | - |
Long Term Investments | $196M |
Short Term Investments | $184M |
Other Current Assets | $19M |
Other Non Current Assets | - |
Total Liabilities | $111M |
Total Current Liabilities | $37M |
Current Accounts Payable | $5.2M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $2.6M |
Total Non Current Liabilities | $74M |
Capital Lease Obligations | $7.1M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $7.1M |
Other Current Liabilities | $26M |
Other Non Current Liabilities | $18M |
Total Shareholder Equity | $830M |
Treasury Stock | - |
Retained Earnings | $499M |
Common Stock | $20K |
Common Stock Shares Outstanding | $18M |
Field | Value (USD) |
---|---|
Operating Cashflow | $97M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $38M |
Capital Expenditures | $1.8M |
Change In Receivables | - |
Change In Inventory | $9.6M |
Profit Loss | - |
Cashflow From Investment | -$144M |
Cashflow From Financing | $98M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$5.1M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$4M |
Field | Value (USD) |
---|---|
Gross Profit | $156M |
Total Revenue | $167M |
Cost Of Revenue | $11M |
Costof Goods And Services Sold | $11M |
Operating Income | -$23M |
Selling General And Administrative | $79M |
Research And Development | $21M |
Operating Expenses | $179M |
Investment Income Net | - |
Net Interest Income | $5M |
Interest Income | $8.1M |
Interest Expense | $3M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $35M |
Income Before Tax | $2.5M |
Income Tax Expense | $6.6M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$4M |
Comprehensive Income Net Of Tax | - |
Ebit | $5.6M |
Ebitda | $41M |
Net Income | -$4M |
Field | Value |
---|---|
Ex Dividend Date | 2010-07-02 |
Declaration Date | None |
Record Date | None |
Payment Date | None |
Amount | 0.08 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.